- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Relmada Therapeutics Inc (RLMD)
The Relmada Therapeutics share price today is 4.540, view NASDAQ RLMD stock exchange data. Track the latest Relmada Therapeutics share price with real-time updates on RLMD stock performance including market cap, day range, 52-week range and dividend yield. Access RLMD charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.505
4.935
52 wk Range
0.550
8.000
RLMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.5054.935
52 wk Range
0.5508.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RLMD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
12.667
Upside
+179.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 8K Relmada Therapeutics Inc For: 6 August- Investing.com
Relmada names Bipin Dalmia as chief business officer- Investing.com
- Form 8K Relmada Therapeutics Inc For: 6 August
- Investing.com
- Relmada names Bipin Dalmia as chief business officer
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.667
(+179.00% Upside)
Relmada Therapeutics Inc Earnings Call Summary for Q2/2026
- Relmada posted Q2 2026 loss of $0.11/share, beating consensus estimate of $0.19/share by 42.1%, though shares fell 4.28% after-hours to $5.14.
- Cash position surged 134% to $217.7M from $93M at year-end 2025, providing runway through 2029 including Phase III program for lead drug NDV-01.
- Company targets IND filing for bladder cancer drug NDV-01 by year-end 2026, with 80 clinical sites enrolled ahead of Phase III rescue program launch.
- R&D spending tripled to $8.4M from $2.8M year-over-year as NDV-01 and sepranolone programs advance; G&A expenses declined 10.8% to $6.6M.
- Analysts maintain 'Strong Buy' rating with price targets of $9-$19, though manufacturing delays and execution risk on Phase III timeline weigh on sentiment.
Last Updated: 07-08-2026, 02:44 am
Read Full TranscriptEarnings
Latest Release
06-08-2026
EPS / Forecast
-0.11 / -0.19
Revenue / Forecast
-- / --
Compare RLMD to Peers and Sector
Metrics to compare | RLMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.8x | −10.5x | −0.4x | |
PEG Ratio | −0.14 | −0.92 | 0.00 | |
Price/Book | 2.3x | 8.0x | 2.6x | |
Price / LTM Sales | - | 53.5x | 3.1x | |
Upside (Analyst Target) | 142.9% | 119.4% | 48.5% | |
Fair Value Upside | Unlock | −8.1% | 5.8% | Unlock |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Relmada Therapeutics (RLMD) Share Price Today?
The Relmada Therapeutics share price today is 4.540.
What is the current Relmada Therapeutics (RLMD) share price and day range?
As of 10-08-2026, the Relmada Therapeutics share price is 4.540, with a previous close of 4.940. The share price has ranged from 4.505 to 4.935 today, while the 52-week range spans from 0.550 to 8.000.
What Is the Relmada Therapeutics Market Cap?
As of today, Relmada Therapeutics market cap is 486.410M.
What Is the Relmada Therapeutics (RLMD) Share Price Target?
The average 12-month share price target for Relmada Therapeutics is 12.667, with a high estimate of 19 and a low estimate of 9. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +179.00% Upside potential.
What Is Relmada Therapeutics's Earnings Per Share (TTM)?
The Relmada Therapeutics EPS (TTM) is -0.846.
When Is the Next Relmada Therapeutics Earnings Date?
Relmada Therapeutics will release its next earnings report on 05-11-2026.
From a Technical Analysis Perspective, Is RLMD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Relmada Therapeutics Trade On?
Relmada Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Relmada Therapeutics?
The stock symbol for Relmada Therapeutics is "RLMD."
How Many Times Has Relmada Therapeutics Stock Split?
Relmada Therapeutics has split 2 times.
How Many Employees Does Relmada Therapeutics Have?
Relmada Therapeutics has 17 employees.
What Is the RLMD Premarket Price?
RLMD's last pre-market stock price is 5.000. The pre-market share volume is 2,930.000, and the stock has changed by 0.060, or 1.210%.
What Is the RLMD After Hours Price?
RLMD's last after hours stock price is 4.620, the stock has changed by 0.080, or 1.760%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.